Braveheart Bio, Inc. is a clinical stage biopharmaceutical company. The Company is focused on developing therapies for patients with hypertrophic cardiomyopathy (HCM) and other serious cardiovascular diseases. Its lead product candidate, BHB 1893, is an oral small-molecule cardiac myosin inhibitor (CMI), that it is developing for the treatment of obstructive HCM (oHCM) and non-obstructive HCM (nHCM). Its pipeline is focused on advancing BHB-1893 across multiple cardiovascular indications with significant unmet need. HCM is a chronic, progressive disease characterized by abnormal thickening and impaired relaxation of the heart.
Back to dashboard
Company Information
About this company
Key people
Christopher A. Viehbacher
Independent Chairman of the Board
Vineeta Agarwala
Independent Director
Jasper Bos
Independent Director
Travis Murdoch
President, Chief Executive Officer, Director
J. Paul Rickey
Chief Financial Officer
Marc Evanchik
Chief Scientific Officer
Michele Anderson
Chief Development Officer
Tyler Chavez
Chief Business Officer
Emil Degoma
Chief Medical Officer
Jason Coloma
Director
David Malek
Director
Click to see more
Key facts
- Shares in issue76.34m
- EPICBRVE
- ISINUS10567X1019
- LocationUnited States
- SectorHealthcare
- IndustryBiotechnology & Drugs
- Market capGBX 0.00
- Employees30
- ExchangeNASDAQ
- Index
- Website
Data policy - All information should be used for indicative purposes only. You should independently check data before making any investment decision. HL cannot guarantee that the data is accurate or complete, and accepts no responsibility for how it may be used. Overview data is sourced from Refinitiv.